Rapid Micro Biosystems, Inc.

NASDAQ:RPID

Medical - Devices

Healthcare
$1.11 +1.49%

+$0.03 today

Market cap
$50.31M
Beta
1.46
P/E (TTM)
-1.5
EPS (TTM)
-$1.10
52W Low $1.66High $4.94

Volume 0.17M

Average 0.18M

RPID Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Rapid Micro Biosystems, Inc.NASDAQ: RPID

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $3.36M fell 7.3% year over year, in line with the -7.2% change in trailing-twelve-month research & development. Sequentially, it rose 4.3% from the prior quarter. Over 3 fiscal years it compounded at +1.9% a year.

Context

  • Research & development amounted to 40.5% of revenue in FY2025, down 11.5 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -7.3% toward the trailing-twelve-month pace of -7.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.36M+4.3% QoQ
Last fiscal yearDec 2025
$13.6M-6.8% YoY
LTMMar 2026
$13.34M-7.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.3%——
1 year-6.8%——
3-year CAGR+1.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
13.6M USD
Year-over-year change
-6.8%
4-year CAGR
+8.6%

Research & Development vs competitors

How RPID compares with its peers on the latest reported figures

  • RPID's LTM Mar 2026 research & development of $13.34M is the 5th highest of the 9 companies compared; the peer median is $14M.
  • Its year-over-year change of -7.2% is the 5th highest of 9, against a peer median of -6.9%.
  • Research & development amounts to 38.8% of revenue for RPID, versus a peer median of 21.0%.
RPID Competitors Peer median
Research & Development for RPID and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGTXCognition Therapeutics, Inc.LTM Mar 2026$32.45M -22.6%+7.0%—
RCELAVITA Medical, Inc.LTM Mar 2026$20.18M -5.9%+14.6%27.9%
VANIVivani Medical, Inc.LTM Mar 2026$18.17M +11.9%+8.6%—
OWLTOwlet, Inc.LTM Mar 2026$15.13M +46.7%-20.4%14.1%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$13.34M -7.2%+1.9%38.8%
SERASera Prognostics, Inc.LTM Mar 2026$12.87M -10.5%-2.6%22573.7%
LNSRLENSAR, Inc.LTM Mar 2026$5.47M +1.0%-21.9%9.5%
LUCDLucid Diagnostics Inc.LTM Mar 2026$5.46M -7.8%+691.2%106.3%
APYXApyx Medical CorporationLTM Mar 2026$3.33M -25.7%-9.5%6.0%
Peer median (excluding RPID) $14M-6.9%+2.2%21.0%

Competitors are the stored peer set for RPID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue23.23M17.13M22.52M28.05M33.59M
Cost of Revenue30.97M25.67M28M28.16M25.98M
Gross Profit(7.74M)(8.54M)(5.49M)(109K)7.61M
Gross Margin-33.3%-49.8%-24.4%-0.4%22.7%
Research & Development9.78M12.87M12.82M14.6M13.6M
Selling, General & Admin29.71M41.81M38.26M35.21M34.84M
Operating Expenses39.49M54.68M51.08M49.81M55M
Depreciation & Amortization1.53M2.84M3.11M3.36M3.25M
EBITDA(69.25M)(58.55M)(49.33M)(43.51M)(42.74M)
EBITDA Margin-298.1%-341.7%-219.1%-155.1%-127.3%
Operating Income(47.23M)(63.22M)(56.56M)(49.92M)(47.39M)
Operating Margin-203.3%-369.0%-251.2%-178.0%-141.1%
Interest Income01.78M4.21M3.16M1.51M
Interest Expense2.65M0001.09M
Other Income / Expenses(26.2M)1.84M4.13M3.05M309K
Income Before Tax(73.43M)(61.38M)(52.44M)(46.87M)(47.08M)
Pre-Tax Margin-316.1%-358.3%-232.9%-167.1%-140.2%
Income Tax Expense91K(576K)31K22K40K
Net Income(73.52M)(60.81M)(52.47M)(46.89M)(47.12M)
Net Margin-316.5%-354.9%-233.0%-167.2%-140.3%
EPS (Basic)(1.88)(1.43)(1.22)(1.08)(1.05)
EPS (Diluted)(1.88)(1.43)(1.22)(1.08)(1.05)
Weighted Avg Shares41.47M42.45M43.02M43.58M44.68M
Weighted Avg Shares (Diluted)41.47M42.45M43.02M43.58M44.68M

Rapid Micro Biosystems, Inc.

NASDAQ:RPID

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.